Opening stock page...
Fetching company snapshot, pricing, and intelligence.
Intelligence coverage: 60%
Basic profile, financials, and market data are shown below. Deep research is building in the background.
AI confidence 70% · prior close shown (market closed)
Dianthus Therapeutics, Inc. /DE/ shows decelerating business momentum based on AlphaOS pipeline evidence.
3 signals not yet derived from pipeline evidence
Pipeline evidence · 6d ago
DNTH's AlphaOS Signals
Upgrade to Pro for validated historical pattern analysis on DNTH.
Free accounts see more of this; Premium sees all of it.
Reported figures for Dianthus Therapeutics, Inc. /DE/ — research only, not investment advice.
Updated
What happened recently for Dianthus Therapeutics, Inc. /DE/ (DNTH) — events, not interpretation.
Research & analysis only — not investment advice.
Investment snapshot
DNTH's AI investment thesis
Upgrade to Premium for DNTH's full multi-agent investment thesis.
Free accounts see more of this; Premium sees all of it.
Unified data coverage and cross-signal highlights — market, SEC, earnings, opportunity
Strengthen intelligence
Prior close
$98.35
Market cap
$5.50B
Profitable
No
Revenue $2.04M
Net income
$-162.34M
FY Dec 31, 2025
Loading Wall Street consensus…
Loading earnings intelligence…
Building technical intelligence snapshot — check back shortly.
Loading market context…
No price history. Sync market data to load charts.
Loading SEC filing intelligence…
No filings ingested yet.
Investment Snapshot above is the primary AlphaOS analysis for Dianthus Therapeutics, Inc. /DE/ — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.
Research & analysis only — not investment advice. Price, charts, and filings are above.
Follow Dianthus Therapeutics, Inc. /DE/ through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.
Connected companies and research pages from the AlphaOS knowledge graph.